The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 07, 2014

Filed:

Feb. 08, 2011
Applicants:

Rene Hen, Tenafly, NJ (US);

Kenji Tanaka, Kanagawa, JP;

Inventors:

Rene Hen, Tenafly, NJ (US);

Kenji Tanaka, Kanagawa, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/00 (2006.01); C12N 5/00 (2006.01); C07H 21/00 (2006.01); A01K 67/027 (2006.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C07H 21/00 (2013.01); A01K 2227/105 (2013.01); C12N 2800/107 (2013.01); A01K 67/0275 (2013.01); A01K 2217/072 (2013.01); A01K 2217/075 (2013.01); C12N 2830/003 (2013.01); C12N 2800/30 (2013.01); A01K 2217/206 (2013.01); C12N 15/8509 (2013.01); C12N 15/85 (2013.01); A01K 2217/203 (2013.01);
Abstract

Disclosed is a FAST (Flexible Accelerated STOP TetO-knockin) system, an efficient method for manipulating gene expression in vivo to rapidly screen animal models of disease. This invention further discloses a single gene targeting event yielding 2 distinct knockin mice—STOP-tetO and tetO knockin—which permit generation of multiple strains with variable expression patterns: 1) knockout, 2) Cre-mediated rescue; 3) tTA-mediated misexpression; 4) tTA-mediated overexpression; and 5) tTS-mediated conditional knockout/knockdown. Using the FAST system, multiple gain- and loss-of-function strains can therefore be generated on a timescale not previously achievable. These strains can then be screened for clinically-relevant abnormalities. The flexibility and broad applicability of the FAST system is demonstrated by targeting several genes encoding proteins implicated in neuropsychiatric disorders: Mlc1, Neuroligin 3, the serotonin 1A receptor, and the serotonin 1B receptor.


Find Patent Forward Citations

Loading…